Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Biosite in Cardiovascular Biomarker Collaboration

NEW YORK, Feb. 10 - Ciphergen Biosystems and Biosite have begun a collaboration to discover antibody and protein target components for use in diagnostic assays for cardiovascular disease, the companies said today.

 

Biosite will provide clinical samples that Ciphergen scientists will analyze using its ProteinChip technology. The companies will search for differentially expressed protein biomarkers that may be useful as diagnostics or with therapeutic potential.

 

Biosite plans to develop antibodies against key biomarkers discovered in this collaboration. Both firms are entitled to royalties from any products successfully developed and commercialized as a result of the research.

 

The project will initially focus on cardiovascular disease, an area in which Biosite has already commercialized several diagnostic systems.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.